Brian Turpin

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Funda Meric-Bernstam, Ryma Benayed, Marc Ladanyi, 2018, The New England journal of medicine.

The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

David M. Hyman, David S. Hong, Alberto S. Pappo, 2017 .